IPSC Stock — Century Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Our beta islet, T cell and NK cell programs are allogeneic, meaning they are derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.68

Market cap

$304.2M

Cash

$197.2M

Enterprise value

$107.0M

Balance sheet

Cash	$197.2M
Debt	$0.0M
Net cash	$197.2M
Enterprise value	$107.0M
Basic shares	181.1M shares
Fully diluted shares	196.8M shares
Fully diluted market cap	$330.5M
Cash per share	$1.09
Quarterly burn	$19.8M
Cash runway	9.9 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

181.1M

Pre-funded warrants

0.0M

Options

15.1M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.6M

FDSO

196.8M

Cap table as of 2026-06-30.

Price history

Loading IPSC daily closes…

Loading price history…

Next catalyst

CNTY-813 · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	CNTY-813 first-in-human in type 1 diabetes	Not disclosed	type 1 diabetes	IND Q4 2026; data H2 2027
Sep 12 - Oct 24 in 22 mo	CNTY-101	Phase 1	Systemic Lupus Erythematosus; Lupus Nephritis; Idiopathic Inflammatory Myopathies	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

CNTY-813

Preclinical · Active Modality: cell therapy (iPSC-derived beta islet cell replacement)

Indications

Type 1 diabetes (T1D) (Preclinical)

Catalysts

— 2026

Status note Lead product candidate: iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0, designed to protect from T cell, NK cell and humoral immune rejection for durable glycemic control without chronic immunosuppression. In IND-enabling studies (announced Nov 2025). Preclinical data: restored normoglycemia maintained for over 4 months in a diabetic mouse model.

CNTY-308

Preclinical · Active Modality: cell therapy (iPSC-derived CD4+/CD8+ CAR-iT cell)

Target CD19

Indications

B-cell-mediated diseases (Preclinical)

Catalysts

— 2026

Status note CD19-targeted CD4+/CD8+ alpha-beta CAR-iT cell therapy engineered with Allo-Evasion 5.0, designed for off-the-shelf treatment of B-cell-mediated diseases. In IND-enabling studies; functionally comparable to primary T cells in preclinical testing.

CNTY-101

Phase 1 · Active Modality: cell therapy (iPSC-derived CAR-iNK cell)

Target CD19

Partnerships Phase 1/2 investigator-sponsored trial (CARAMEL) sponsored by Friedrich-Alexander University Erlangen-Nurnberg (Professors Georg Schett and Andreas Mackensen). BMS collaboration on iNK/iT programs terminated without cause Mar 2025.

Indications

SLE / lupus nephritis (Phase 1)
Idiopathic inflammatory myopathy (IIM) (Phase 1)
Diffuse cutaneous systemic sclerosis (DcSSc) (Phase 1)

Catalysts

— 2026

Status note First therapeutic candidate: off-the-shelf iPSC-derived CAR-iNK incorporating CD19 CAR, secreted IL15, EGFR safety switch and six precision edits (Allo-Evasion 1.0). Phase 1/2 CARAMEL IST currently enrolling and dosing patients with B-cell-mediated autoimmune diseases (SLE, lupus nephritis, IIM, DcSSc); initial data presented Dec 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CNTY-101
Lead indication	Systemic Lupus Erythematosus
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06255028	Phase 1	Active, not recruiting	Sponsor	IPSC	—	Systemic Lupus Erythematosus; Lupus Nephritis; Idiopathic Inflammatory Myopathies	—
NCT05768269	Not disclosed	Recruiting	Sponsor	IPSC	—	Hematological Malignancy; Solid Tumor Malignancy	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Century Therapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	17,754,430	no change	0.38%	2026-08-14
RTW Investments	8,695,652	no change	0.18%	2026-08-14
DAFNA Capital	2,400,458	-33,895	1.12%	2026-08-14
Casdin Capital	1,228,190	no change	0.15%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

IPSC — Century Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

IPSC — Century Therapeutics Inc.